Dashboard
Manage Tickers

AXNX Axonics, Inc.

Nasdaq axonics.com


$ 0.53 (0.75 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.32 $ 4.22 (0.71 %)
DIA $ 463.02 $ 0.00 (0 %)
SPY $ 664.84 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.55 $ 6.60 (1.73 %)
$ 70.98
-- x --
-- x --
-- - --
$ 55.09 - $ 71.05
4,233,308
na
3.63B
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2024 09-30-2024 10-Q
2 08-01-2024 06-30-2024 10-Q
3 04-30-2024 03-31-2024 10-Q
4 02-29-2024 12-31-2023 10-K
5 10-30-2023 09-30-2023 10-Q
6 07-31-2023 06-30-2023 10-Q
7 05-02-2023 03-31-2023 10-Q
8 03-01-2023 12-31-2022 10-K
9 11-09-2022 09-30-2022 10-Q
10 08-01-2022 06-30-2022 10-Q
11 05-05-2022 03-31-2022 10-Q
12 03-01-2022 12-31-2021 10-K
13 11-04-2021 09-30-2021 10-Q
14 08-05-2021 06-30-2021 10-Q
15 05-07-2021 03-31-2021 10-Q
16 03-01-2021 12-31-2020 10-K
17 11-04-2020 09-30-2020 10-Q
18 08-06-2020 06-30-2020 10-Q
19 05-05-2020 03-31-2020 10-Q
20 03-04-2020 12-31-2019 10-K
21 11-14-2019 09-30-2019 10-Q
22 08-05-2019 06-30-2019 10-Q
23 05-08-2019 03-31-2019 10-Q
24 03-05-2019 12-31-2018 10-K
25 12-11-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-hold-on-axonics
Needham Reiterates Hold on Axonics
11/08/2024 16:51:29

Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.

axonics-q3-sales-11620m-beat-11350m-estimate-eps-000-vs-008-yoy
Axonics Q3 Sales $116.20M Beat $113.50M Es...
11/07/2024 22:04:41

Axonics (NASDAQ:AXNX) reported quarterly sales of $116.20 million which beat the analyst consensus estimate of $113.50 million ...

australia-therapeutic-goods-administration-has-approved-for-marketing-axonics-r20-rechargeable-sacral-neuromodulation-system-for-overactive-bladder-and-fecal-incontinence--axonics-expects-to-commence-sales-of-the-r20-to-australian-customers-in-november
Australia Therapeutic Goods Administration...
09/26/2024 10:05:04

Core News & Articles
Reported Earlier, Axonics Prevails In Pate...
09/19/2024 07:24:36

needham-reiterates-hold-on-axonics
Needham Reiterates Hold on Axonics
08/05/2024 17:04:43

Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.

axonics-receives-approval-from-the-therapeutic-goods-administration-for-marketing-of-axonics-f15-in-australia
Axonics Receives Approval From The Therape...
05/16/2024 20:07:59

needham-reiterates-hold-on-axonics
Needham Reiterates Hold on Axonics
05/06/2024 14:10:46

Needham analyst Mike Matson reiterates Axonics (NASDAQ:AXNX) with a Hold.

axonics-q1-eps-038-misses-008-estimate-sales-9141m-beat-8959m-estimate
Axonics Q1 EPS $(0.38) Misses $(0.08) Esti...
04/30/2024 20:31:29

Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by ...

fda-classifies-boston-scientifics-recall-for-device-to-stop-blood-flow-as-most-serious
FDA Classifies Boston Scientific's Recall ...
04/18/2024 14:02:35

Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolizatio...

Core News & Articles
Boston Scientific Earlier Disclosed That O...
04/04/2024 12:55:38

Core News & Articles
Axonics Stockholders Approve Merger Agreem...
03/22/2024 20:01:54

Axonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston...

Core News & Articles
Axonics Updates On Inter Partes Review Pro...
03/21/2024 20:58:35

Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's ‘314 patent and declined to invalidate the challe...

axonics-announced-that-the-axonics-r20-rechargeable-sacral-neuromodulation-snm-system-has-received-ce-mark-approval
Axonics Announced That The Axonics R20 Rec...
03/14/2024 10:06:35

Core News & Articles
Axonics Responds To ITC Action By Medtroni...
02/29/2024 21:20:45

Axonics, Inc. (NASDAQ:AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. Inte...

beyond-the-numbers-7-analysts-discuss-axonics-stock
Beyond The Numbers: 7 Analysts Discuss Axo...
02/29/2024 17:01:32

rbc-capital-reiterates-sector-perform-on-axonics-maintains-71-price-target
RBC Capital Reiterates Sector Perform on A...
02/29/2024 16:52:43

RBC Capital analyst Shagun Singh reiterates Axonics (NASDAQ:AXNX) with a Sector Perform and maintains $71 price target.

axonics-q4-eps-013-beats-006-estimate-sales-10973m-beat-10733m-estimate
Axonics Q4 EPS $0.13 Beats $0.06 Estimate,...
02/28/2024 21:04:26

Axonics (NASDAQ:AXNX) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116....

why-medical-devices-giant-boston-scientific-shares-are-rising-today
Why Medical Devices Giant Boston Scientifi...
01/31/2024 14:27:31

Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlo...

needham-downgrades-axonics-to-hold
Needham Downgrades Axonics to Hold
01/17/2024 11:01:33

Needham analyst Mike Matson downgrades Axonics (NASDAQ:AXNX) from Buy to Hold.

truist-securities-downgrades-axonics-to-hold-lowers-price-target-to-71
Truist Securities Downgrades Axonics to Ho...
01/16/2024 20:34:11

Truist Securities analyst David Rescott downgrades Axonics (NASDAQ:AXNX) from Buy to Hold and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION